Medical experts divided on whether 2nd FDA-approved Alzheimer’s drug provides a benefit

But doctors and health experts are divided on whether it warranted an accelerated FDA approval. While some of them have praised the agency’s decision, describing the drug as groundbreaking, others are skeptical about whether it provides a substantial benefit.

In the U.S., over 6 million people are living with Alzheimer’s, an incurable and fatal disease that affects the brain and causes loss of cognitive function over time. While there are available medications that can treat Alzheimer’s symptoms, there have been no treatments that address the underlying cause of the disease. This is why some doctors have welcomed the accelerated approval of lecanemab. The FDA is likely to consider a full approval later this year.

Source: Medical experts divided on whether 2nd FDA-approved Alzheimer’s drug provides a benefit

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: